- Home
- KMDA vs DOMO Comparison
KMDA vs DOMO Comparison
Compare KMDA & DOMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMDA
- DOMO
- Stock Information
- Founded
- KMDA 1990
- DOMO 2010
- Country
- KMDA Israel
- DOMO United States
- Employees
- KMDA N/A
- DOMO N/A
- Industry
- KMDA Biotechnology: Pharmaceutical Preparations
- DOMO Computer Software: Prepackaged Software
- Sector
- KMDA Health Care
- DOMO Technology
- Exchange
- KMDA Nasdaq
- DOMO Nasdaq
- Market Cap
- KMDA 399.7M
- DOMO 436.2M
- IPO Year
- KMDA N/A
- DOMO 2018
- Fundamental
- Price
- KMDA $6.85
- DOMO $14.63
- Analyst Decision
- KMDA Strong Buy
- DOMO Hold
- Analyst Count
- KMDA 3
- DOMO 6
- Target Price
- KMDA $14.67
- DOMO $10.67
- AVG Volume (30 Days)
- KMDA 80.5K
- DOMO 912.6K
- Earning Date
- KMDA 05-14-2025
- DOMO 05-21-2025
- Dividend Yield
- KMDA 2.92%
- DOMO N/A
- EPS Growth
- KMDA 31.21
- DOMO N/A
- EPS
- KMDA 0.28
- DOMO N/A
- Revenue
- KMDA $167,235,000.00
- DOMO $317,052,000.00
- Revenue This Year
- KMDA $14.51
- DOMO $1.71
- Revenue Next Year
- KMDA $9.31
- DOMO $2.43
- P/E Ratio
- KMDA $23.98
- DOMO N/A
- Revenue Growth
- KMDA 11.83
- DOMO N/A
- 52 Week Low
- KMDA $4.74
- DOMO $6.01
- 52 Week High
- KMDA $9.16
- DOMO $14.78
- Technical
- Relative Strength Index (RSI)
- KMDA 52.85
- DOMO 87.33
- Support Level
- KMDA $6.64
- DOMO $12.33
- Resistance Level
- KMDA $6.99
- DOMO $13.53
- Average True Range (ATR)
- KMDA 0.17
- DOMO 0.85
- MACD
- KMDA -0.02
- DOMO 0.35
- Stochastic Oscillator
- KMDA 58.00
- DOMO 96.89
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
About DOMO Domo Inc. Class B
Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.